Halozyme Therapeutics, Inc. (HALO)
Automate Your Wheel Strategy on HALO
With Tiblio's Option Bot, you can configure your own wheel strategy including HALO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HALO
- Rev/Share 9.7136
- Book/Share 2.7422
- PB 24.4219
- Debt/Equity 4.5353
- CurrentRatio 8.3606
- ROIC 0.2863
- MktCap 7833213020.0
- FreeCF/Share 4.4559
- PFCF 14.4874
- PE 14.5822
- Debt/Assets 0.7347
- DivYield 0
- ROE 1.3663
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HALO | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Aug. 6, 2025 |
| Resumed | HALO | Goldman | -- | Neutral | -- | $55 | July 10, 2025 |
| Downgrade | HALO | Morgan Stanley | Overweight | Equal Weight | -- | $62 | May 14, 2025 |
| Downgrade | HALO | Leerink Partners | Market Perform | Underperform | -- | $47 | May 13, 2025 |
| Downgrade | HALO | Wells Fargo | Overweight | Equal Weight | $58 | $62 | Oct. 7, 2024 |
| Downgrade | HALO | JP Morgan | Overweight | Neutral | $52 | $57 | Sept. 19, 2024 |
News
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, …
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Read More
5 Biotech Stocks Worth Adding to Your Portfolio Now
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
Read More
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Read More
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Read More
Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Helen Torley - President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone. Welcome to Morgan Stanley's Global Healthcare Conference.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
Published: September 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
Read More
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Read More
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for September 3rd
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Read More
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Read More
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Identify Superstar Stocks Like Halozyme with Money Flows
Published: August 29, 2025 by: FXEmpire
Sentiment: Positive
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Read More
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma," said Dr. Helen …
Read More
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody …
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Read More
About Halozyme Therapeutics, Inc. (HALO)
- IPO Date 2004-03-16
- Website https://www.halozyme.com
- Industry Biotechnology
- CEO Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employees 350